Peter E. Carson
Impact in
- Cardiology and Cardiovascular Medicine top 0.02%
- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Blood Pressure and Hypertension Studies
-
- Diabetes Treatment and Management
Papers in
-
- Heart Failure Treatment and Management 65
- Cardiovascular Function and Risk Factors 26
- Cardiac pacing and defibrillation studies 23
- Cardiac electrophysiology and arrhythmias 9
- Atrial Fibrillation Management and Outcomes 7
- Cardiac Arrhythmias and Treatments 5
- Co-authors
- Michael R. Bristow (15 shared papers)Arthur M. Feldman (12 shared papers)Michael R. Zile (43 shared papers)David L. DeMets (3 shared papers)Michel Komajda (41 shared papers)John Boehmer (8 shared papers)John J.V. McMurray (43 shared papers)Leslie A. Saxon (7 shared papers)
- Journals
- Circulation (20 papers)Journal of the American College of Cardiology (16 papers)JACC Heart Failure (12 papers)European Journal of Heart Failure (11 papers)Circulation Heart Failure (10 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Peter E. Carson
136 papers receiving 18.1k citations
Peter E. Carson's Hit Papers
Peers
Comparison fields: 5 of 159
- Cardiology and Cardiovascular Medicine 15.0k
- Endocrinology, Diabetes and Metabolism 1.4k
- Complementary and alternative medicine 467
- Family Practice 79
- Nephrology 246
Countries citing papers authored by Peter E. Carson
This map shows the geographic impact of Peter E. Carson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter E. Carson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter E. Carson more than expected).
Fields of papers citing papers by Peter E. Carson
This network shows the impact of papers produced by Peter E. Carson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter E. Carson. The network helps show where Peter E. Carson may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter E. Carson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 139 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure Hit paper breakdown → | 2004 | 4180 |
| 2 | A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure Hit paper breakdown → | 1991 | 2145 |
| 3 | Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction Hit paper breakdown → | 2008 | 1431 |
| 4 | Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure Hit paper breakdown → | 2004 | 1225 |
| 5 | Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure Hit paper breakdown → | 1996 | 883 |
| 6 | Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction Hit paper breakdown → | 2011 | 396 |
| 7 | 1999 | 385 | |
| 8 | 1993 | 366 | |
| 9 | 2005 | 325 | |
| 10 | 2002 | 296 | |
| 11 | Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction Hit paper breakdown → | 2020 | 285 |
| 12 | 1999 | 284 | |
| 13 | 2011 | 270 | |
| 14 | The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. | 1993 | 268 |
| 15 | 2010 | 259 | |
| 16 | Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial Hit paper breakdown → | 2021 | 235 |
| 17 | 2007 | 220 | |
| 18 | 2006 | 216 | |
| 19 | 2010 | 198 | |
| 20 | 2015 | 195 |
About Peter E. Carson
Peter E. Carson is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Complementary and alternative medicine, Pulmonary and Respiratory Medicine and Economics and Econometrics, having authored 139 papers that have together received 19.2k indexed citations. Recurring topics across this work include Heart Failure Treatment and Management (65 papers), Cardiovascular Function and Risk Factors (26 papers), Cardiac pacing and defibrillation studies (23 papers), Cardiac electrophysiology and arrhythmias (9 papers), Cardiovascular and exercise physiology (7 papers), Atrial Fibrillation Management and Outcomes (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Cardiac Arrhythmias and Treatments (5 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (15.0k citations), Endocrinology, Diabetes and Metabolism (1.4k citations), Complementary and alternative medicine (467 citations), Family Practice (79 citations) and Nephrology (246 citations). Peter E. Carson has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Michael R. Bristow, Arthur M. Feldman, Michael R. Zile, David L. DeMets, Michel Komajda, John Boehmer, John J.V. McMurray, Leslie A. Saxon, Robert S. McKelvie and Steven K. Krueger. Their work appears in journals such as Circulation, Journal of the American College of Cardiology, JACC Heart Failure, European Journal of Heart Failure and Circulation Heart Failure.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.